Search
Insulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalto produce or synthesize the insulin needed to manage circulating blood sugar levels. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.
Ceftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalthe convenience of daily or twice-daily dosing. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Products: NOVOSEF 1 G/10 ML IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET, NOVOSEF 1 G/3,5 ML IM ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADETPhylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigational[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity … [L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]
Synonyms: 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinoneFlorquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease … [L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Categories: Peripheral Opioid Receptor AntagonistsEtripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational) to sinus rhythm in adults. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Venlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADAWarfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion … Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration.
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational2019 under the brand name Padcev<sup>TM</sup>. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.